Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV

Current Topics in Medicinal Chemistry

Volumn 8, Issue 17, 2008, Pages 1545-1552

  Gwaltney II, Stephen L ^a  

^a Takeda San Diego Inc   (United States)

Author keywords

Alogliptin; Dipeptidyl Peptidase IV (DPP 4); Glucagon like Peptide 1 (GLP 1); Linagliptin (Ondero ); Saxagliptin (Onglyza ); Sitagliptin (Januvia ; Vildagliptin (Galvus )

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; 8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYNYL) 3 METHYL 1 (4 METHYL 2 QUINAZOLINYLMETHYL)XANTHINE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; LINAGLIPTIN; ONGLYZA; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; TRIAZOLOPIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; NITRILE; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; URACIL;

CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HYPOGLYCEMIA; IC 50; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; REVIEW; SIDE EFFECT; SKIN TOXICITY; STRUCTURE ACTIVITY RELATION; WEIGHT GAIN; CHEMISTRY; DRUG ANTAGONISM;

ADAMANTANE; ANTIGENS, CD26; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; NITRILES; PIPERIDINES; PYRROLIDINES; URACIL;

EID: 59149106467     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608786413519     Document Type: Review

References (50)

1. Zhu, L.; Tamvakopoulos, C.; Xie, D.; Dragovic, J.; Shen, X.; Fenyk-Melody, J.E.; Schmidt, K.; Bagchi, A.; Griffin, P.R.; Thornberry, N.A.; Roy, R. S. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides. J. Biol. Chem. 2003, 278, 22418-22423.
2. Holst, J.J. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab. Res. Rev. 2002, 18, 430-441.
3. Zander, M.; Madsbad, S.; Madsen, J.L.; Holst, J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359, 824-830.
4. Holst, J.J. Treatment of type two diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Exp. Opin. Emerg. Drugs 2004, 9, 155-166.
5. Mentlein, R. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. Exp. Opin. Investig. Drugs 2005, 14, 57-64.
6. Sinclair, E.M.; Drucker, D.J. Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhbitors: new therapeutic agents for the treatment of type 2 diabetes. Curr. Opin. Endocrinol. Diabet., 2005, 12, 146-151.
7. Holst, J.J.; Deacon, C.F. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr. Opin. Pharmacol. 2004, 4, 589-596.
8. Hinke, S.A.; Kuhn-Wache, K.; Hoffmann, T.; Pederson, R.A.; McIntosh, C.H.S.; Demuth, H.-U. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem. Biophys. Res. Comm. 2002, 291, 1302-1308.
9. Deacon, C.F.; Holst, J.J. Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Biochem. Biophys. Res. Comm. 2002, 294, 1-4.
10. Demuth, H.-U.; Hinke, S.A.; Pederson, R.A.; McIntosh, C.H.S. Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective." Biochem. Biophys. Res. Comm. 2002, 296, 229-232.
11. Villhauer, E.B.; Coppola, G.M.; Hughes, T.E. DPP-IV inhibition and therapeutic potential. Ann. Rep. Med. Chem. 2001, 36, 191-200.
12. Wiedeman, P.E.; Trevillyan, J.M. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr. Opin. Investig. Drugs 2003, 4, 412-420.
13. Deacon, C.F.; Ahrén, B.; Holst, J.J. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Exp. Opin. Investig. Drugs 2004, 13, 1091-1102.
14. Weber, A.E. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem. 2004, 47, 4135-4141.
15. Gwaltney, II, S. L.; Stafford, J. A. Inhibitors of Dipeptidyl Peptidase 4. Ann. Reports Med. Chem. 2005, 40, 149-165.
16. Okubo, A.; Nishioka, H.; Arai, H.; Tanaka, Y.; Kato, H.; Nakata, N. World Patent 1991/18877, 1991.
17. Li, J.; Wilk, E.; Wilk, S. Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidyl-peptidase IV (CD26). Arch. Biochem. Biophys. 1995, 323, 148-154.
18. Ashworth, D.M.; Atrash, B.; Baker, G.R.; Baxter, A.J.; Jenkins, P.D.; Jones, D.M.; Szelke, M. 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 1996, 6, 1163-1166.
19. Villhauer, E.B.; Brinkman, J.A.; Naderi, G.B.; Dunning, B.E.; Mangold, B.L.; Mone, M.D.; Russell, M.E.; Weldon, S.C.; Hughes, T.E. 1-[2-[(5-Cyanopyridin-2-yl)amino]-ethylamino]acetyl-2-(S)pyrrolidine- carbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 2002, 45, 2362-2365.
20. Ahrén, B.; Simonsson, E.; Larsson, H.; Landin-olsson, M.; Torgeirsson, H.; Jansson, P.-A.; Sandqvist, M.; Bavenholm, P.; Efendic, S.; Eriksson, J.W.; Dickinson, S.; Holmes, D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25, 869-875.
21. Villhauer, E.B.; Brinkman, J.A.; Naderi, G.B.; Burkey, B.F.; Dunning, B.E.; Prasad, K.; Mangold, B.L.; Russell, M.E.; Hughes, T.E. 1- (3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 2003, 46, 2774-2789.
22. Ahrén, B.; Landin-Olsson, M.; Jansson, P.-A.; Svensson, M.; Holmes, D.; Schweizer, A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 2004, 89, 2078-2084.
23. Ahrén, B.; Gomis, R.; Standl, E.; Mills, D.; Schweizer, A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27, 2874-2880.
24. Novartis press release, November 13, 2006.
25. Novartis press release, February 26, 2007.
26. Hanessian, S.; Reinhold, U.; Saulnier, M.; Claridge, S. Probing the importance of spacial and conformational domains in captopril analogs for angiotensin converting enzyme activity. Bioorg. Med. Chem. Lett. 1998, 8, 2123-2128.
27. Hanessian, S.; Reinhold, U.; Gentile, G. The synthesis of enantiopure ω-methanoprolines and ω-methanopipecolic acids by a novel cyclopropanation reaction: the "flattening" of proline. Angew. Chem., Int. Ed. Engl. 1997, 36, 1881-1884.
28. Magnin, D.R.; Robl, J.A.; Sulsky, R.B.; Augeri, D.J.; Huang, Y; Simpkins, L.M.; Taunk, P.C.; Betebenner, D.A.; Robertson, J.G.; Abboa-Offei, B.E.; Wang, A; Cap, M.; Xin, L.; Tao, L.; Sitkoff, D.F.; Malley, M.F.; Gougoutas, J.Z.; Khanna, A.; Huang, Q.; Han, S.-P.; Parker, R.A.; Hamann, L.G. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of α-aminoacyl-L-cis-4,5-methanoprolinenitrile-based inhbitors. J. Med. Chem. 2004, 47, 2587-2598.
29. Augeri, D.J.; Robl, J.A.; Betebenner, D.A.; Magnin, D.R.; Khanna, A.; Robertson, J.G.; Wang, A; Simpkins, L.M.; Taunk, P.C.; Huang, Q.; Han, S.-P.; Abboa-Offei, B.E.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G.E.; Egan, D.M.; Marcinkeviciene, J.; Chang, S.Y.; Biller, S.A.; Kirby, M.S.; Parker, R.A.; Hamann, L.G. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48, 5025-5037.
30. Rosenstock, J.; Sankoh, S.; List, J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes, Obesity Metab. 2008, 10, 376-386.
31. Bristol-Myers Squibb press release, July 23, 2008.
32. Weber, A. E.; Thornberry, N. Case history: Januvia™ (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann. Reports Med. Chem. 2007, 42, 95-109.
33. Thornberry, N.A.; Weber, A. E. Discovery of Januvia™ (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr. Top. Med. Chem. 2007, 7, 557-568.
34. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G.J.; Fisher, M.H.; He, H.; Hickey, G.J.; Kowalchick, J.E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M.E.; Patel, R.A.; Petrov, A.; Scapin, G.; Patel, S.B.; Roy, R.S.; Wu, J.K.; Wyvratt, M.J.; Zhang, B.B.; Zhu, L.; Thornberry, N.A.; Weber, A.E. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5, 6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4, 5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2005, 48, 141-151.
35. Himmelsbach, F., Mark, M., Eckhardt, M., Langkopf, E., Maier, R., Lotz, R. World Patent 2002/068420, 2002.
36. Kanstrup, A.B.; Christiansen, L.B.; Lundbeck, J.M.; Sams, C.K.; Kristiansen, M. World Patent 2002/02560, 2002.
37. Eckhardt,M.; Langkopf, E.; Mark,M.; Tadayyon,M.; Thomas,L.; Nar, H.; Pfrengle, W.; Guth, B.; Lotz, R.; Sieger, P.; Fuchs, H.; Himmelsbach, F. 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl -1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2007, 50, 6450-6453.
38. Lankas, G.R.; Leiting, B.; Roy, R.S.; Eiermann, G.J.; Beconi, M.G.; Biftu, T.; Chan, C.-C.; Edmondson, S.; Feeney, W.P.; He, H.; Ippolito, D.E.; Kim, D.; Lyons, K.A.; Ok, H.O.; Patel, R.A.; Petrov, A.N.; Pryor, K.A.; Qian, X.; Reigle, L.; Woods, A.; Wu, J.K.; Zaller, D.; Zhang, X.; Zhu, L.; Weber, A.E.; Thornberry, N.A. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Diabetes, 2005, 54, 2988-2994.
39. Forst, T.; Uhlig-Laske, B; Ring, A; Ritzhaupt, A; Graefe-Mody, U; Dugi, K.A. The novel, potent, and selective DPP-IV inhibitor BI 1356 significantly lowers HbA1c after only 4 weeks of treatment in patients with type 2 diabetes. Presented at the 2007 American Diabetes Association Meeting, Chicago, IL, United States, June 22-26, 2007; 594-P.
40. Hosfield, D., Palan, J., Hilgers, M., Scheibe, D., McRee , D.E., and Stevens, R.C. A fully integrated protein crystallization platform for small-molecule drug discovery. J. Struct. Biol., 2003, 142, 207-217.
41. Mountain, V. Astex, Structural Genomix, and Syrrx. I can see clearly now: structural biology and drug discovery. Chem. Biol. 2003, 10, 95-98.
42. Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.; Kassel, D. B.; Navre, M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D. R.; Gwaltney, S. L. Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem. 2007, 50, 2297-2300.
43. Hansotia, T.; Baggio, L.L.; Delmeire, D.; Hinke, S.A.; Yamada, Y.; Tsukiyama, K.; Seino, Y.; Holst, J.J.; Schuit, F.; Drucker, D.J. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes, 2004, 53, 1326-1335.
44. Christopher, R.; Covington, P.; Davenport, M.; Fleck, P.; Mekki, Q.; Wann, E.; Karim, A.; Pharmacokinetics, pharmacodynamics and tolerability of multiple doses of alogliptin benzoate (SYR-322), a dipeptidyl peptidase-IV inhibitor, in patients with type 2 diabetes. Presented at the 2007 American Diabetes Association Meeting, Chicago, IL, United States, June 22-26, 2007; 499-P.
45. DeFronzo, R.; Fleck, P.; Wilson, C.; Mekki, Q. Alogliptin monotherapy improves glycemic control in patients with type 2 diabetes. Presented at the 2008 American Diabetes Association Meeting, San Francisco, CA, United States, June 6-10, 2008; 446-P.
46. Fleck, P.; Christopher, R.; Covington, P.; Wilson, C.; Mekki, Q. Efficacy and safety of alogliptin monotherapy in patients with type 2 diabetes. Presented at the 2008 American Diabetes Association Meeting, San Francisco, CA, United States, June 6-10, 2008; 479-P.
47. Rosenstock, J.; Rendell, M.; Gross, J.L.; Fleck, P.; Wilson, C.; Mekki, Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without increasing weight gain or hypoglycemia. Presented at the 2008 American Diabetes Association Meeting, San Francisco, CA, United States, June 6-10, 2008; 444-P.
48. Pratley, R.; Kipnes, M.; Fleck, P.; Wilson, C.; Mekki, Q. Alogliptin added to sulfonylurea therapy in patients with type 2 diabetes reduces HbA1c without increasing hypoglycemia. Presented at the 2008 American Diabetes Association Meeting, San Francisco, CA, United States, June 6-10, 2008; 445-P.
49. Nauck, M.; Ellis, G.; Fleck, P.; Wilson, C.; Mekki, Q. Efficacy and safety of alogliptin added to metformin therapy in patients with type 2 diabetes. Presented at the 2008 American Diabetes Association Meeting, San Francisco, CA, United States, June 6-10, 2008; 447-P.
50. Pratley, R.; Reusch, J.; Fleck, P.; Wilson, C.; Mekki, Q. Efficacy and safety of alogliptin added to pioglitazone therapy in patients with type 2 diabetes. Presented at the 2008 American Diabetes Association Meeting, San Francisco, CA, United States, June 6-10, 2008; 448-P.